

# Bengt JÄnsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2419250/publications.pdf>

Version: 2024-02-01

95  
papers

5,820  
citations

117625

34  
h-index

74163

75  
g-index

99  
all docs

99  
docs citations

99  
times ranked

7450  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543.	4.6	7
2	Value appropriation in hepatitis C. <i>European Journal of Health Economics</i> , 2021, , 1.	2.8	2
3	Propelling Health Care into the Twenties. <i>Biomedicine Hub</i> , 2020, 5, 1-53.	1.2	9
4	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , 2020, 14, 1589-1615.	4.6	33
5	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020, 2, 100142.	4.9	53
6	The cost of cancer in Europe 2018. <i>European Journal of Cancer</i> , 2020, 129, 41-49.	2.8	182
7	A comparative study on costs of cancer and access to medicines in Europe.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19051-e19051.	1.6	4
8	Efficiency and productivity of cancer care in Europe. <i>Journal of Cancer Policy</i> , 2019, 21, 100194.	1.4	4
9	Mission-oriented translational cancer research – health economics. <i>Molecular Oncology</i> , 2019, 13, 636-647.	4.6	9
10	Cost of Cancer: Healthcare Expenditures and Economic Impact. <i>Recent Results in Cancer Research</i> , 2019, 213, 7-23.	1.8	6
11	Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. <i>European Journal of Health Economics</i> , 2019, 20, 427-438.	2.8	85
12	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. <i>Quality of Life Research</i> , 2018, 27, 707-716.	3.1	36
13	Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 239-249.	2.2	72
14	Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study. <i>BMC Psychiatry</i> , 2018, 18, 80.	2.6	6
15	Assessment of value for resource allocation in cancer care. <i>Journal of Cancer Policy</i> , 2017, 11, 12-18.	1.4	2
16	Disruptive innovation and EU health policy. <i>European Journal of Health Economics</i> , 2017, 18, 269-272.	2.8	10
17	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 609-619.	0.5	5
18	Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2151-2165.	2.2	44

#	ARTICLE	IF	CITATIONS
19	The Three-Way Pendulum of Healthcare Innovation. Biomedicine Hub, 2017, 2, 1-4.	1.2	0
20	Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status.. Journal of Clinical Oncology, 2017, 35, 6535-6535.	1.6	1
21	The cost and burden of cancer in the European Union 1995â€“2014. European Journal of Cancer, 2016, 66, 162-170.	2.8	99
22	Drug utilization research in the area of cancer drugs. , 2016, , 315-327.		0
23	The End of the International Reference Pricing System?. Applied Health Economics and Health Policy, 2016, 14, 1-8.	2.1	37
24	The burden and direct cost of cancer in Europe (EU-28).. Journal of Clinical Oncology, 2016, 34, 6618-6618.	1.6	7
25	Access to cancer drugs in Europe years 2005-2014.. Journal of Clinical Oncology, 2016, 34, e18015-e18015.	1.6	1
26	Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?. Journal of Clinical Oncology, 2016, 34, 6620-6620.	1.6	0
27	UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH. International Journal of Technology Assessment in Health Care, 2015, 31, 363-370.	0.5	6
28	RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH. International Journal of Technology Assessment in Health Care, 2015, 31, 371-379.	0.5	2
29	Bringing in health technology assessment and costâ€“effectiveness considerations at an early stage of drug development. Molecular Oncology, 2015, 9, 1025-1033.	4.6	18
30	Cost-Effectiveness Analysis Alongside Clinical Trials IIâ€“An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.3	539
31	Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation. Value in Health, 2014, 17, 707-713.	0.3	55
32	Cost effectiveness in practice and its effect on clinical outcomes. Journal of Cancer Policy, 2014, 2, 12-21.	1.4	9
33	The value of tamoxifen and trastuzumab in breast cancer treatment: A study based on uptake and use in Sweden.. Journal of Clinical Oncology, 2014, 32, 589-589.	1.6	1
34	The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer. Chinese Clinical Oncology, 2014, 3, 23.	1.2	2
35	Technology Assessment for New Oncology Drugs. Clinical Cancer Research, 2013, 19, 6-11.	7.0	27
36	Cancer vaccines and immunotherapeutics. Human Vaccines and Immunotherapeutics, 2012, 8, 1360-1363.	3.3	14

#	ARTICLE	IF	CITATIONS
37	Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases. <i>Medical Care</i> , 2012, 50, 1076-1085.	2.4	18
38	Principles for planning and conducting comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 431-440.	1.4	16
39	CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 159-165.	0.5	30
40	Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 2063-2065.	3.1	4
41	Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. <i>European Journal of Health Economics</i> , 2011, 12, 263-271.	2.8	54
42	Relative effectiveness and the European pharmaceutical market. <i>European Journal of Health Economics</i> , 2011, 12, 97-102.	2.8	16
43	Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 967-982.	3.1	106
44	Osteoporosis: burden, health care provision and opportunities in the EU. <i>Archives of Osteoporosis</i> , 2011, 6, 59-155.	2.4	459
45	A 3-year lifestyle intervention for adults at moderate to high risk of cardiovascular disease is cost effective when added to standard care and improves physical health-related quality of life. <i>Evidence-Based Medicine</i> , 2011, 16, 70-71.	0.6	0
46	An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. <i>Archives of Osteoporosis</i> , 2010, 5, 19-48.	2.4	18
47	EBM, HTA, and CER: Clearing the Confusion. <i>Milbank Quarterly</i> , 2010, 88, 256-276.	4.4	140
48	Evaluating HTA principles. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 429-430.	0.5	2
49	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 71-78.	0.5	52
50	Ten arguments for a societal perspective in the economic evaluation of medical innovations. <i>European Journal of Health Economics</i> , 2009, 10, 357-359.	2.8	196
51	Being NICE is not the problem!. <i>European Journal of Cancer</i> , 2009, 45, 1100-1102.	2.8	3
52	Patient access to rheumatoid arthritis treatments. <i>European Journal of Health Economics</i> , 2008, 8, 35-38.	2.8	8
53	IQWiG: an opportunity lost?. <i>European Journal of Health Economics</i> , 2008, 9, 205-207.	2.8	15
54	Key principles for the improved conduct of health technology assessments for resource allocation decisions. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 244-258.	0.5	356

#	ARTICLE	IF	CITATIONS
55	Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Monthly Notices of the Royal Astronomical Society: Letters, 2008, 79, 269-280.	3.3	90
56	Health technology assessment: Regulators or payersâ€”Who will take the lead?. Clinical Therapeutics, 2008, 30, 960-963.	2.5	4
57	The societal burden of osteoporosis in Sweden. Bone, 2007, 40, 1602-1609.	2.9	110
58	Health related quality of life in different states of breast cancer. Quality of Life Research, 2007, 16, 1073-1081.	3.1	183
59	Cost of breast cancer in Sweden in 2002. European Journal of Health Economics, 2007, 8, 5-15.	2.8	61
60	Economic evaluation for pharmaceuticals in Germany. European Journal of Health Economics, 2007, 8, 1-2.	2.8	5
61	Time for a common standard for cost-effectiveness in Europe?. European Journal of Health Economics, 2006, 7, 223-224.	2.8	8
62	Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporosis International, 2006, 17, 637-650.	3.1	272
63	Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. Journal of Hypertension, 2005, 23, 1425-1431.	0.5	16
64	Cost-effectiveness of new drugs: A systematic review of published evidence for new chemical entity drugs introduced on the Swedish market 1987â€”2000. International Journal of Technology Assessment in Health Care, 2005, 21, 187-193.	0.5	1
65	Changing health environment: The challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics, 2004, 22, 5-10.	3.3	70
66	Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?. Value in Health, 2004, 7, 518-528.	0.3	647
67	A review of European studies on the economic burden of brain diseases. European Journal of Health Economics, 2004, 5, s4-s4.	2.8	0
68	Excess mortality after hospitalisation for vertebral fracture. Osteoporosis International, 2004, 15, 108-112.	3.1	250
69	An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respiratory Medicine, 2004, 98, 1146-1154.	2.9	24
70	Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of stockholmâ€”a stochastic model of exercise and dietary advice. Preventive Medicine, 2003, 36, 403-409.	3.4	29
71	Costs of Dementia: A Review. , 2003, , 341-387.		2
72	Costs of Dementia: A Review. , 2002, , 335-381.		5

#	ARTICLE	IF	CITATIONS
73	Commentary. European Journal of Health Economics, 2002, 3, 139-139.	2.8	0
74	Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden. Pharmacoeconomics, 2001, 19, 901-916.	3.3	30
75	A COMPUTER MODEL TO ANALYZE THE COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY. International Journal of Technology Assessment in Health Care, 1999, 15, 352-365.	0.5	32
76	Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis and Rheumatism, 1999, 42, 347-356.	6.7	159
77	Costs of Mini Mental State Examination-Related Cognitive Impairment. Pharmacoeconomics, 1999, 16, 409-416.	3.3	65
78	The Economic Cost of Multiple Sclerosis in Sweden in 1994. Pharmacoeconomics, 1998, 13, 597-606.	3.3	62
79	Economic Evaluation Alongside Multinational Clinical Trials: Study Considerations for GUSTO IIb. International Journal of Technology Assessment in Health Care, 1997, 13, 49-58.	0.5	33
80	The cost of a hip fracture: Estimates for 1,709 patients in Sweden. Acta Orthopaedica, 1997, 68, 13-17.	1.4	98
81	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	148
82	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	1
83	Impact of Inhaled Corticosteroids on Acute Asthma Hospitalization in Sweden. Medical Care, 1996, 34, 1188-1198.	2.4	51
84	Cost-effectiveness: a new criterion for selecting therapy. Journal of Internal Medicine, 1995, 237, 1-3.	6.0	10
85	The Cost Effectiveness of Helicobacter pylori Eradication versus Maintenance and Episodic Treatment in Duodenal Ulcer Patients in Sweden. Pharmacoeconomics, 1995, 8, 410-427.	3.3	24
86	What Price Depression?. British Journal of Psychiatry, 1994, 164, 665-673.	2.8	216
87	Economic evaluation and clinical uncertainty: Response to Freemantle and Maynard. Health Economics (United Kingdom), 1994, 3, 305-307.	1.7	8
88	Cost-Effectiveness of Omeprazole and Ranitidine in the Treatment of Duodenal Ulcer. Pharmacoeconomics, 1994, 5, 44-55.	3.3	7
89	Pricing and Reimbursement of Pharmaceuticals in Sweden. Pharmacoeconomics, 1994, 6, 51-60.	3.3	28
90	Cost-Effectiveness of Antihypertensive Treatment. Pharmacoeconomics, 1993, 3, 36-44.	3.3	14

#	ARTICLE	IF	CITATIONS
91	Economic Evaluation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1993, 4, 173-186.	3.3	58
92	Drug Expenditure and New Drug Introductions. <i>Pharmacoeconomics</i> , 1993, 4, 215-225.	3.3	12
93	Cost-effectiveness of Misoprostol in Sweden. <i>International Journal of Technology Assessment in Health Care</i> , 1992, 8, 234-244.	0.5	46
94	A Review of Cost-Effectiveness Analyses of Hypertension Treatment. <i>Pharmacoeconomics</i> , 1992, 1, 250-264.	3.3	40
95	Economic Evaluation of Drug Therapy. <i>Pharmacoeconomics</i> , 1992, 1, 325-337.	3.3	20